TrialSignal transduction and targeted therapy2024

Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study.

Luling Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.